日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review]

[鲁索替尼联合维奈托克和阿扎胞苷治疗JAK1、JAK3和STAT5B基因突变的难治性T细胞急性淋巴细胞白血病患者：病例报告和文献复习]

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.cn121090-20240412-00138
Xu, P P; Zhou, T; Xu, Y Y; Peng, M X; Du, Y; Xie, T; Yang, Y G; Ouyang, J; Chen, B
T细胞
T细胞
JAK1
JAK3
免疫/内分泌
JAK/STAT
白血病
细胞生物学
发表日期：2024
文献求助 收藏

[Clinicopathologic characteristics and survival analysis of primary large B-cell lymphoma of the central nervous system]

【中枢神经系统原发性大B细胞淋巴瘤的临床病理特征及生存分析】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.cn121090-20231126-00278
Xu, Q F; Shen, R; Shen, Y G; Cao, Y W; Qian, Y; Xu, P P; Cheng, S; Wang, L; Zhao, W L
B细胞
淋巴瘤
神经科学
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

[Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas]

【胰腺原发性和继发性弥漫性大B细胞淋巴瘤的临床特征和预后】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.01.010
Huo, Y J; Zhang, M C; Shi, Q; Qin, W; Shi, Z Y; Wang, L; Cheng, S; Xu, P P; Zhao, W L
淋巴瘤
细胞生物学
B细胞
免疫/内分泌
发表日期：2023
文献求助 收藏

[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin]

[布伦妥昔单抗治疗CD30阳性淋巴瘤的进展]

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.01.018
Cai, M C; Xu, P P; Zhao, W L
淋巴瘤
CD3
CD30
发表日期：2023
文献求助 收藏

[Current researches and progresses on new antibody drugs in the treatment of relapsed/refractory diffuse large B-cell lymphoma]

【复发/难治性弥漫性大B细胞淋巴瘤新型抗体药物的研究进展】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.03.016
Xu, P P; Zhao, W L
淋巴瘤
细胞生物学
B细胞
免疫/内分泌
发表日期：2023
文献求助 收藏

[Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma]

【睾丸弥漫性大B细胞淋巴瘤的临床病理特征及预后分析】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.04.010
Wang, Y; Shi, Z Y; Shi, Q; Wang, S; Zhang, M C; Shen, R; He, Y; Qiu, H L; Yi, H M; Dong, L; Wang, L; Cheng, S; Xu, P P; Zhao, W L
淋巴瘤
细胞生物学
B细胞
免疫/内分泌
发表日期：2023
文献求助 收藏

[Clinical characteristics and efficacy analysis of 11 patients with primary cutaneous diffuse large B-cell lymphoma, leg type]

【11例原发性皮肤弥漫性大B细胞淋巴瘤（腿型）患者的临床特征及疗效分析】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.08.015
Yuan, Y X; Shi, Q; He, Y; Qiu, H L; Yi, H M; Dong, L; Wang, L; Cheng, S; Xu, P P; Zhao, W L
淋巴瘤
细胞生物学
B细胞
免疫/内分泌
发表日期：2023
文献求助 收藏

[Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center]

[单中心对30例重度血友病A成年患者使用低/中剂量凝血因子Ⅷ疗效的分析]

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.01.007
Yuan, Y H; Xu, P P; Xu, Y Y; Liu, S; Shao, X Y; Zhang, W J; Gong, L; Zhou, M; Chen, B; Zhou, R F
发表日期：2023
文献求助 收藏

[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma]

【苯达莫司汀联合利妥昔单抗治疗复发性滤泡性淋巴瘤的临床因素分析】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2022.06.012
Zhao, F; Cheng, L L; Zheng, Z; Zhang, M C; Cheng, S; Xu, P P; Wang, L; Zhao, W L
淋巴瘤
发表日期：2022
文献求助 收藏

[Hereditary coagulation factor XIII deficiency: three cases report and literaure review]

【遗传性凝血因子XIII缺乏症：三例病例报告及文献复习】

期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2021.03.014
Xu, P P; Ding, B J; Li, M J; Liu, J P; Liu, L; Xia, A; Liu, W Q; Zhou, K S; Zhao, H F; Zhou, H; Song, Y P
发表日期：2021
文献求助 收藏